- Home
- APPS vs TRDA Comparison
APPS vs TRDA Comparison
Compare APPS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- TRDA
- Stock Information
- Founded
- APPS 2007
- TRDA 2016
- Country
- APPS United States
- TRDA United States
- Employees
- APPS N/A
- TRDA N/A
- Industry
- APPS Multi-Sector Companies
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- TRDA Health Care
- Exchange
- APPS Nasdaq
- TRDA Nasdaq
- Market Cap
- APPS 534.2M
- TRDA 502.9M
- IPO Year
- APPS N/A
- TRDA 2021
- Fundamental
- Price
- APPS $2.72
- TRDA $9.04
- Analyst Decision
- APPS Hold
- TRDA Strong Buy
- Analyst Count
- APPS 4
- TRDA 3
- Target Price
- APPS $2.38
- TRDA $25.67
- AVG Volume (30 Days)
- APPS 4.1M
- TRDA 91.4K
- Earning Date
- APPS 05-27-2025
- TRDA 05-06-2025
- Dividend Yield
- APPS N/A
- TRDA N/A
- EPS Growth
- APPS N/A
- TRDA N/A
- EPS
- APPS N/A
- TRDA 1.68
- Revenue
- APPS $483,577,000.00
- TRDA $210,782,000.00
- Revenue This Year
- APPS N/A
- TRDA N/A
- Revenue Next Year
- APPS $6.49
- TRDA N/A
- P/E Ratio
- APPS N/A
- TRDA $5.40
- Revenue Growth
- APPS N/A
- TRDA 63.38
- 52 Week Low
- APPS $1.18
- TRDA $8.85
- 52 Week High
- APPS $6.86
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- APPS 37.98
- TRDA 26.54
- Support Level
- APPS $3.24
- TRDA $9.75
- Resistance Level
- APPS $3.80
- TRDA $10.87
- Average True Range (ATR)
- APPS 0.30
- TRDA 0.53
- MACD
- APPS -0.07
- TRDA -0.05
- Stochastic Oscillator
- APPS 8.33
- TRDA 7.57
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.